Evidence map›Paper›PMID 39927143›Full record

ReviewHeliyon2025

Precision oncology through next generation sequencing in hepatocellular carcinoma.

Sayali Shinde, Carola Maria Bigogno, Ana Simmons, Nikita Kathuria, Aruni Ghose, Vedika Apte, Patricia Lapitan, Shania Makker, Aydin Caglayan, Stergios Boussios

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sayali ShindeBarts Cancer Institute, Queen Mary University of London, Cancer Research UK Barts Centre, London, UK.
Carola Maria BigognoDepartment of Medical Oncology, St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Ana SimmonsFaculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Nikita KathuriaFaculty of Life Sciences and Medicine, King's College London, London, UK.
Aruni GhoseDepartment of Medical Oncology, St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Vedika ApteUniversity College London Medical School, London, UK.
Patricia LapitanSchool of Medical Sciences, The University of Manchester, Manchester, UK.
Shania MakkerUniversity College London Cancer Institute, London, UK.
Aydin CaglayanDepartment of Medical Oncology, Medway NHS Foundation Trust, Kent, UK.
Stergios BoussiosDepartment of Medical Oncology, Medway NHS Foundation Trust, Kent, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a primary liver cancer that originates from underlying inflammation, often associated with Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infections. Despite the availability of treatments, there are high rates of tumour relapse due to the development of drug resistance in infected cells. Next-Generation Sequencing (NGS) plays a crucial role in overcoming this issue by sequencing both viral and host genomes to identify mutations and genetic heterogeneity. The knowledge gained from sequencing is then utilised to develop countermeasures against these mutants through different combination therapies. Advances in NGS have led to sequencing with higher accuracy and throughput, thereby enabling personalized and effective treatments. The purpose of this article is to highlight how NGS has contributed to precision medicine in HCC and the possible integration of artificial intelligence (AI) to bolster the advancement.

Indexed as

Artificial intelligenceHepatocellular carcinomaNext generation sequencingPrecision oncologyVirus

Identifiers

PMID39927143
PMCPMC11804570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.